Aspergillosis

Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am. 2006 Sep;20(3):545-61, Abstract

Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1-e60.Full text  Abstract

Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016 Jan;47(1):45-68.Full text  Abstract

Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015 Mar;70(3):270-7.Full text  Abstract

Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38.Full text  Abstract

Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005 Oct;5(10):609-22. Abstract

Maghrabi F, Denning DW. The management of chronic pulmonary aspergillosis: the UK National Aspergillosis Centre approach. Curr Fungal Infect Rep. 2017;11(4):242-51.Full text  Abstract

Limper AH, Knox KS, Sarosi GA, et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011 Jan 1;183(1):96-128.Full text  Abstract

1. Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am. 2006 Sep;20(3):545-61, Abstract

2. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1-e60.Full text  Abstract

3. Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016 Jan;47(1):45-68.Full text  Abstract

4. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015 Mar;70(3):270-7.Full text  Abstract

5. Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017 Oct 18;3(4):57.Full text  Abstract

6. Vallabhaneni S, Benedict K, Derado G, et al. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013. Open Forum Infect Dis. 2017 Jan 13;4(1):ofw268.Full text  Abstract

7. Osman M, Al Bikai A, Rafei R, et al. Update on invasive fungal infections in the Middle Eastern and North African region. Braz J Microbiol. 2020 Dec;51(4):1771-89.Full text  Abstract

8. Webb BJ, Ferraro JP, Rea S, et al. Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network. Open Forum Infect Dis. 2018 Aug;5(8):ofy187.Full text  Abstract

9. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore). 2000 Jul;79(4):250-60. Abstract

10. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005 May;43 Suppl 1:S49-58. Abstract

11. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001 Dec 1;33(11):1824-33.Full text  Abstract

12. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in United States, 1980-1997. Clin Infect Dis. 2001 Sep 1;33(5):641-7.Full text  Abstract

13. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998 Sep;37(2):173-80. Abstract

14. Page ID, Byanyima R, Hosmane S, et al. Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Eur Respir J. 2019 Mar 18;53(3):1801184.Full text  Abstract

15. Anon. Aspergilloma and residual tuberculous cavities-the results of a resurvey. Tubercle. 1970 Sep;51(3):227-45. Abstract

16. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38.Full text  Abstract

17. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005 Oct;5(10):609-22. Abstract

18. Walsh TJ, Groll AH. Overview: non-fumigatus species of Aspergillus: perspectives on emerging pathogens in immunocompromised hosts. Curr Opin Investig Drugs. 2001 Oct;2(10):1366-7. Abstract

19. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003 Jul 15;188(2):305-19.Full text  Abstract

20. Mays SR, Bogle MA, Bodey GP. Cutaneous fungal infections in the oncology patient: recognition and management. Am J Clin Dermatol. 2006;7(1):31-43. Abstract

21. Roilides E, Katisfa H, Walsh TJ. Pulmonary host defences against Aspergillus fumigatus. Res Immunol. 1998 May-Jun;149(4-5):454-65 Abstract

22. Jahn B, Boukhallouk F, Lotz J, et al. Interaction of human phagocytes with pigmentless Aspergillus conidia. Infect Immun. 2000 Jun;68(6):3736-9.Full text  Abstract

23. Ibrahim-Granet O, Philippe B, Boleti H, et al. Phagocytosis and intracellular fate of Aspergillus fumigatus conidia in alveolar macrophages. Infect Immun. 2003 Feb;71(2):891-903.Full text  Abstract

24. Gersuk GM, Underhill DM, Zhu L, et al. Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol. 2006 Mar 15;176(6):3717-24.Full text  Abstract

25. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008 Oct 23;359(17):1766-77.Full text  Abstract

26. Gago S, Denning DW, Bowyer P. Pathophysiological aspects of Aspergillus colonization in disease. Med Mycol. 2019 Apr 1;57(suppl 2):S219-27.Full text  Abstract

27. Aslam PA, Eastridge CE, Hughes FA Jr. Aspergillosis of the lung: an eighteen-year experience. Chest. 1971 Jan;59(1):28-32. Abstract

28. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002 Dec 15;100(13):4358-66.Full text  Abstract

29. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002 Jan;29(1):15-9. Abstract

30. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997 Jun;175(6):1459-66. Abstract

31. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984 Mar;100(3):345-51. Abstract

32. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis. 2005 Aug;18(4):342-5. Abstract

33. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis. 2002 Jul 1;35(1):53-61.Full text  Abstract

34. Winkelstein JA, Marino MC, Johnston RB Jr., et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore). 2000 May;79(3):155-69. Abstract

35. Gallin JI, Zarember K. Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease. Trans Am Clin Climatol Assoc. 2007;118:175-85. Abstract

36. Almyroudis NG, Holland SM, Segal BH. Invasive aspergillosis in primary immunodeficiencies. Med Mycol. 2005 May;43 Suppl 1:S247-59. Abstract

37. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Med Mycol. 2005 May;43 Suppl 1:S267-70. Abstract

38. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in the type of transplant and implications for management. J Heart Lung Transplant. 2003 Mar;22(3):258-66. Abstract

39. Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S281-92.Full text  Abstract

40. Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant. 2004 Apr;4(4):636-43.Full text  Abstract

41. Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002 Nov;8(11):1065-70. Abstract

42. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis. 2005 Jul 1;41(1):52-9.Full text  Abstract

43. Kawamura S, Maesaki S, Tomono, K, et al. Clinical evaluation of 61 patients with pulmonary aspergilloma. Intern Med. 2000 Mar;39(3):209-12.Full text  Abstract

44. Zizzo G, Castriota-Scanderbeg A, Zarrelli N, et al. Pulmonary aspergillosis complicating ankylosing spondylitis. Radiol Med. 1996 Jun;91(6):817-8. Abstract

45. Rosenheim SH, Schwarz, J. Cavitary pulmonary cryptococcosis complicated by aspergilloma. Am Rev Respir Dis. 1975 Apr;111(4):549-53. Abstract

46. Sarosi GA, Silberfarb PM, Saliba NA, et al. Aspergillomas occurring in blastomycotic cavities. Am Rev Respir Dis. 1971 Oct;104(4):581-4. Abstract

47. Addrizzo-Harris DJ, Harkin TJ, McGuinness G. Pulmonary aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest. 1997 Mar;111(3):612-8. Abstract

48. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007 Oct;30(4):782-800.Full text  Abstract

49. Samarakoon P, Soubani AO. Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature. Chron Respir Dis. 2008;5(1):19-27. Abstract

50. Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018 Oct;6(10):782-92. Abstract

51. Mitaka H, Kuno T, Takagi H, et al. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses. 2021 Sep;64(9):993-1001. Abstract

52. Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991 Mar 7;324(10):654-62. Abstract

53. Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis. 2000 Nov;31(5):1253-7.Full text  Abstract

54. Mylonakis E, Barlam TF, Flanigan T, et al. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest. 1998 Jul;114(1):251-62. Abstract

55. Pursell KJ, Telzak EE, Armstrong D. Aspergillus species colonization and invasive disease in patients with AIDS. Clin Infect Dis. 1992 Jan;14(1):141-8. Abstract

56. Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006 Feb;10(1):R31.Full text  Abstract

57. Zilberberg MD, Harrington R, Spalding JR, et al. Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004-2013. BMC Public Health. 2019 May 17;19(1):591.Full text  Abstract

58. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004 Nov 8;164(20):2206-16.Full text  Abstract

59. Gargani Y, Bishop P, Denning DW. Too many mouldy joints - marijuana and chronic pulmonary aspergillosis. Mediterr J Hematol Infect Dis. 2011;3(1):e2011005.Full text  Abstract

60. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348-59.Full text  Abstract

61. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335-47.Full text  Abstract

62. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003 Jun 12;348(24):2416-22.Full text  Abstract

63. Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016 Sep;95(9):1435-55.Full text  Abstract

64. Partridge-Hinckley K, Liddell GM, Almyroudis NG, et al. Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients. Mycopathologia. 2009 Dec;168(6):329-37. Abstract

65. Anaissie EJ, Costa SF. Nosocomial aspergillosis is waterborne. Clin Infect Dis. 2001 Nov 1;33(9):1546-8.Full text  Abstract

66. Cruciani M, Mengoli C, Barnes R, et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev. 2019 Sep 3;9:CD009551.Full text  Abstract

67. Escuissato D, Gasparetto EL, Marchiori E, et al. Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. AJR Am J Roentgenol. 2005 Sep;185(3):608-15.Full text  Abstract

68. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001 Jan 1;19(1):253-9. Abstract

69. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007 Feb 1;44(3):373-9.Full text  Abstract

70. Zhong H, Wang Y, Gu Y, et al. Clinical features, diagnostic test performance, and prognosis in different subtypes of chronic pulmonary aspergillosis. Front Med (Lausanne). 2022 Feb 11:9:811807.Full text  Abstract

71. Roberts CM, Citron KM, Strickland B. Intrathoracic aspergilloma: role of CT in diagnosis and treatment. Radiology. 1987 Oct;165(1):123-8. Abstract

72. Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis. 2008 Apr;27(4):245-51. Abstract

73. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005 Sep 1;41(5):654-9. Abstract

74. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004 Jul 15;39(2):199-205.Full text  Abstract

75. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004 Aug 1;190(3):641-9.Full text  Abstract

76. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis. 2007 May 15;44(10):1329-36.Full text  Abstract

77. Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis. 2002 Nov 1;186(9):1297-306.Full text  Abstract

78. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001 Mar 15;97(6):1604-10.Full text  Abstract

79. Sulahian A, Boutboul F, Ribaud P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer. 2001 Jan 15;91(2):311-8. Abstract

80. Mennink-Kersten MA, Klont RR, Warris A, et al. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet. 2004 Jan 24;363(9405):325-7. Abstract

81. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med. 2003 Dec 11;349(24):2366-7. Abstract

82. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. 2004 Dec;42(12):5517-22.Full text  Abstract

83. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008 Jan 1;177(1):27-34.Full text  Abstract

84. de Heer K, Gerritsen MG, Visser CE, et al. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2019 May 20;5:CD012399.Full text  Abstract

85. White SK, Schmidt RL, Walker BS, et al. (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database Syst Rev. 2020 Jul 21;(7):CD009833.Full text  Abstract

86. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest. 2002 Jun;121(6):1988-99. Abstract

87. Wilopo BAP, Richardson MD, Denning DW. Diagnostic aspects of chronic pulmonary aspergillosis: present and new directions​. Curr Fungal Infect Rep. 2019 Nov 25;13:292-300.Full text

88. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996 Feb;100(2):171-8. Abstract

89. Takazono T, Izumikawa K. Recent advances in diagnosing chronic pulmonary aspergillosis. Front Microbiol. 2018 Aug 17:9:1810.Full text  Abstract

90. White PL, Linton CJ, Perry MD, et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis. 2006 Feb 15;42(4):479-86.Full text  Abstract

91. Guo YL, Chen YQ, Wang K, et al. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest. 2010 Oct;138(4):817-24. Abstract

92. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006 Sep;20(3):581-607. Abstract

93. Nucci M, Anaissie E. Emerging fungi. Infect Dis Clin North Am. 2006 Sep;20(3):563-79. Abstract

94. Lerner PI. Nocardiosis. Clin Infect Dis. 1996 Jun;22(6):891-903 Abstract

95. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367-76.Full text  Abstract

96. Hage CA, Carmona EM, Epelbaum O, et al. Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2019 Sep 1;200(5):535-50.Full text  Abstract

97. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002 Jan 24;346(4):225-34. Abstract

98. Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother. 2011 Jan;66 Suppl 1:i25-35.Full text  Abstract

99. von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62(6):341-7. Abstract

100. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002 Mar 1;34(5):563-71.Full text  Abstract

101. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001 Mar 1;32(5):686-93.Full text  Abstract

102. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8;347(6):408-15.Full text  Abstract

103. Williams K, Mansh M, Chin-Hong P, et al. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014 Apr;58(7):997-1002.Full text  Abstract

104. Clancy CJ, Nguyen MH. Long-term voriconazole and skin cancer: is there cause for concern? Curr Infect Dis Rep. 2011 Dec;13(6):536-43. Abstract

105. Miller DD, Cowen EW, Nguyen JC, et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010 Mar;146(3):300-4.Full text  Abstract

106. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2005 May 1;40 Suppl 6:S392-400.Full text  Abstract

107. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998 Jun;26(6):1383-96. Abstract

108. Cornely OA, Maertens J, Bresnik M, et al.; AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-load regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007 May 15;44(10):1289-97.Full text  Abstract

109. Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021 Feb 6;397(10273):499-509. Abstract

110. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004 Sep 15;39(6):797-802.Full text  Abstract

111. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006 Feb 15;81(3):320-6. Abstract

112. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004 Dec 1;39(11):1563-71.Full text  Abstract

113. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003 Jul 15;98(2):292-9.Full text  Abstract

114. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005 Nov 1;41(9):1242-50.Full text  Abstract

115. Caillot D, Mannone L, Cuisenier B, et al. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect. 2001;7 Suppl 2:54-61. Abstract

116. Maghrabi F, Denning DW. The management of chronic pulmonary aspergillosis: the UK National Aspergillosis Centre approach. Curr Fungal Infect Rep. 2017;11(4):242-51.Full text  Abstract

117. Uflacker R, Kaemmerer A, Picon PD, et al. Bronchial artery embolization in the management of hemoptysis: technical aspects and long-term results. Radiology. 1985 Dec;157(3):637-44. Abstract

118. Chen JC, Chang YL, Luh SP, et al. Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax. 1997 Sep;52(9):810-3. Abstract

119. Regnard JF, Icard P, Nicolosi M, et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg. 2000 Mar;69(3):898-903.Full text  Abstract

120. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016 Feb 20;387(10020):760-9. Abstract

121. Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015 Jan 20;162(2):81-9. Abstract

122. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995 Jul 15;86(2):457-62.Full text  Abstract

123. Wan L, Zhang Y, Lai Y, et al. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial. J Clin Oncol. 2015 Dec 1;33(34):3999-4006.Full text  Abstract

124. Atallah E, Schiffer CA. Granulocyte transfusion. Curr Opin Hematol. 2006 Jan;13(1):45-9. Abstract

125. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997 Oct;11(10):1621-30. Abstract

126. Monk EJM, Harris C, Döffinger R, et al. Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis: effects on frequency of acute exacerbation and all-cause hospital admission. Thorax. 2020 Jun;75(6):513-6.Full text  Abstract

127. Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia-new drugs and immunotherapy. Best Pract Res Clin Haematol. 2008 Dec;21(4):683-90. Abstract

128. Limper AH, Knox KS, Sarosi GA, et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011 Jan 1;183(1):96-128.Full text  Abstract

129. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017 Mar;102(3):433-44.Full text  Abstract

130. Lowes D, Al-Shair K, Newton PJ, et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J. 2017 Feb 8;49(2):1601062.Full text  Abstract

131. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis. 2006 Jun 1;42(11):1584-91.Full text  Abstract

132. Bongomin F, Otu A, Harris C, et al. Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy. Clin Infect Pract. 2020 Apr;5:100015.Full text

133. Cadena J, Thompson GR 3rd, Patterson TF. Aspergillosis: epidemiology, diagnosis, and treatment. Infect Dis Clin North Am. 2021 Jun;35(2):415-34.Full text  Abstract

134. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet. 2005 Sep 17-23;366(9490):1013-25. Abstract

135. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2.Full text  Abstract

136. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007 Apr 15;109(8):1532-5.Full text  Abstract

137. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin. 2003;19(4):263-71. Abstract